Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $389.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 8686.91% year-over-year to $389.9 million; the TTM figure through Mar 2026 stood at $426.0 million (down 31.89% YoY), while the FY2025 annual figure was $40.6 million, down 96.0% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $389.9 million, up from $26.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $556.2 million in Q4 2024, with the low at $115000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $12.7 million (2023), against an average of $115.2 million.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 99.93% in 2022, then jumped 81216.94% in 2024.
• Crinetics Pharmaceuticals' Cash from Financing Activities stood at $115000.0 in 2022, then jumped by 34870.43% to $40.2 million in 2023, then surged by 1283.12% to $556.2 million in 2024, then sank by 95.32% to $26.0 million in 2025, then surged by 1397.5% to $389.9 million in 2026.
• Business Quant data shows CRNX's Cash from Financing Activities at $389.9 million in Q1 2026, $26.0 million in Q4 2025, and $3.1 million in Q3 2025.